Pivotal Trials of Letrozole: A New Aromatase Inhibitor

ONCOLOGY

Volumn 12, Issue 3 SUPPL. 5, 1998, Pages 41-44

  Smith, Ian E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002735955     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Smith IE, Fitzharris BM, McKinna JA, et al: Aminoglutethimide in the treatment of metastatic breast carcinoma. Lancet 2 646-649, 1978.
2. Smith IE, Harris AL, Morgan M, et al: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial. Br Med J Clin Res Ed 283:1432-1434, 1981
3. Stuart Harris R, Dowsett M, Bozek T, et al: Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet 2:604-607, 1984.
4. Brodie AM, Garrett WM, Hendrickson JR, et al: Inactivation of aromatase in vitro by 4-hydroxy-4 androstene-3, 17-dione and4-acetoxy4-androstene-3,17-dione and sustained effects in vivo. Steroids 38:693-702, 1981.
5. Coombes RC, Hughes SW, Dowsett M: 4-hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer. Eur J Cancer 28a:1941-1945, 1992.
6. Bhatnagar AS, Hausler A, Schieweck K: Inhibition of aromatase in vitro and in vivo by aromatase inhibitors. J Enzyme Inhib 4-179-186, 1990.
7. Iveson TJ, Smith IE, Ahern J, et al: Phase 1 study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 53:266-270, 1993.
8. Dowsett M, Jones A, Johnston SRD, et al: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1:1511-1515, 1995.
9. Demers LM: Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 30-95-102, 1994.
10. Lipton A, Demers LM, Harvey HA, et al: Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer Cancer 75:2132-2138, 1995.
11. Bisagni G, Cocconi G, Scaglione F. et al: Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer: A pilot study. Ann Oncol 7:99-102, 1996.
12. Dombernowsky P, Smith I, Falkson G, et al: Letrozole (Femara), a new oral aromatase inhibitor for advanced breast cancer. Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998.
13. Marty M, Gershanovich M, Campos B, et al: Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens (abstract). Proc Am Soc Clin Oncol 16 156a, 1997.